Clinical trials: Cancer of Kidney
Metastatic Renal Cell Carcinoma
Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney Cancer
This randomized phase II trial studies how well ziv-aflibercept (VEGF Trap) works in treating patients with kidney cancer that has spread from the primary site to other places in the body (metastatic) or is unable to be removed…
- Trial name
- NCT00357760
- Testing
- VEGF Trap
- Where
- 205 sites in United States, Peru
- Volunteers
- 94 people
- Sponsor
- National Cancer Institute (NCI)
Kidney Cancer
PEG-Interferon Alfa-2b, Sargramostim, and Thalidomide in Treating Patients With Metastatic Kidney Cancer
RATIONALE: PEG-interferon alfa-2b may interfere with the growth of tumor cells. Colony-stimulating factors such as sargramostim may increase the number of immune cells found in bone marrow or peripheral blood.
- Trial name
- NCT00090870
- Testing
- PEG-interferon alfa-2b, GM-CSF, thalidomide
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Medical University of South Carolina
Non Small Cell Lung Cancer, Metastatic Melanoma
UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade
This is a phase I/II study that will evaluate the safety and toxicity of this combinatorial approach. Eligible patients >18 years of age with histologically proven metastatic NSCLC, melanoma, RCC, or HNSCC who have failed PD-1 /…
- Conditions
- Non Small Cell Lung Cancer, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT03474497
- Testing
- IL-2, Pembrolizumab, Radiotherapy
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Megan Daly, MD
Fatigue, Recurrent Renal Cell Cancer
Sunitinib Malate Related Fatigue in Patients With Metastatic Kidney Cancer
The purpose of this research study is to determine how sunitinib (sunitinib malate) causes fatigue. Patients will be asked to complete a brief questionnaire (survey) to rate their levels of fatigue every two weeks while they are…
- Conditions
- Fatigue, Recurrent Renal Cell Cancer, Stage IV Renal Cell Cancer
- Trial name
- NCT01740154
- Testing
- transcranial magnetic stimulation, electromyography, survey administration
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Case Comprehensive Cancer Center
Renal Cell Carcinoma, Renal Cancer
Biomarker Trial of Everolimus in Patients With Advanced Renal Cell Carcinoma
The purpose of this study is to determine if certain features of tumor specimens sampled prior to therapy can predict for the likelihood of responding to everolimus.
- Trial name
- NCT00827359
- Testing
- Everolimus
- Where
- 3 sites in United States
- Volunteers
- 25 people
- Sponsor
- Beth Israel Deaconess Medical Center
Advanced Renal Cell Carcinoma
An Extension Treatment Protocol for Subjects Who Have Participated in a Study of Tivozanib Versus Sorafenib in Kidney Carcinoma (Protocol AV-951-09-301).
Open-label, multi-center extension treatment protocol to allow access to tivozanib and sorafenib for subjects who have participated on the AV-951-09-301 protocol.
- Trial name
- NCT01076010
- Testing
- Tivozanib, Sorafenib
- Where
- 75 sites in United States, Bulgaria and 13 more
- Volunteers
- 277 people
- Sponsor
- AVEO Pharmaceuticals, Inc.
Breast Cancer, Colorectal Cancer
Adapting Multiple Behavior Interventions That Effectively Improve Cancer Survivor Health Cancer Survivor Health
This research study will test the efficacy of interactive, web-based interventions that improve diet, physical activity and weight management changes among early stage survivors of breast, prostate, colorectal, endometrial…
- Conditions
- Breast Cancer, Colorectal Cancer, Endometrial Cancer, Kidney Cancer
- Trial name
- AMPLIFY (NCT04000880)
- Testing
- Adapting MultiPLe Behavior Interventions That eFfectively Improve (AMPLIFI) Cancer Survivor Health, Diet-Exercise, Exercise-Diet
- Where
- 2 sites in United States
- Volunteers
- 603 people
- Sponsor
- University of Alabama at Birmingham
Metastatic Clear Cell Renal Cell Carcinoma
A Study of LY2510924 and Sunitinib in Patients With Metastatic Renal Cell Carcinoma
To compare the progression free survival of LY2510924 plus sunitinib therapy versus sunitinib in the first-line setting for patients with metastatic clear-cell renal cell carcinoma.
- Trial name
- NCT01391130
- Testing
- LY2510924, Sunitinib
- Where
- 21 sites in United States
- Volunteers
- 110 people
- Sponsor
- Eli Lilly and Company
Kidney Cancer
Randomized Evaluation of Patients Who Have Had Laparoscopic Partial Nephrectomy
The purpose of this study is to evaluate the necessity of using hemostatic agents as a tool when performing robotic partial nephrectomy in the treatment of kidney cancer.
- Trial name
- NCT04120805
- Testing
- Hemostatic Agent, No Hemostatic Agent
- Where
- United States
- Volunteers
- 208 people
- Sponsor
- University of Chicago
Renal Cell Carcinoma
Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma
The primary purpose of the study is to demonstrate that lenvatinib in combination with everolimus (Arm A) or pembrolizumab (Arm B) is superior compared to sunitinib alone (Arm C) in improving progression-free survival (PFS) (by…
- Trial name
- CLEAR (NCT02811861)
- Testing
- Lenvatinib, Everolimus, Pembrolizumab
- Where
- 183 sites in United States, Australia and 18 more
- Volunteers
- 1,069 people
- Sponsor
- Eisai Inc.
Myeloproliferative Disorder, Urothelial Carcinoma
Phase II Trial of Gemcitabine, Carboplatin, and Bevacizumab in Chemotherapy Naive Patients With Advanced/Metastatic Urothelial Carcinoma
Gemcitabine and carboplatin are two standard chemotherapy drugs used to treat tumors of the urothelial tract. These drugs do not shrink tumors in all patients and when they do, it is generally for a limited amount of time.
- Conditions
- Myeloproliferative Disorder, Urothelial Carcinoma, Cancer
- Trial name
- NCT00588666
- Testing
- Bevacizumab, Carboplatin, Gemcitabine
- Where
- 6 sites in United States
- Volunteers
- 51 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Von-Hippel Lindau, Kidney Disease, Chronic
Contrast-enhanced Ultrasound as a Screening Tool for Kidney Cancer in Patients With Von-Hippel Lindau
The purpose of this study is to determine if contrast-enhanced ultrasound can detect abnormal features of kidney lesions in patients with Von-Hippel Lindau with the same accuracy as conventional ultrasound and contrast-enhanced…
- Trial name
- CEUS-VHL (NCT03907657)
- Testing
- Perflutren lipid microsphere, Sulfur hexafluoride lipid microspheres
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Renal Cell Carcinoma
Intraoperative Folate Targeted Fluorescence in Renal Cell Carcinoma
Primary To explore the use of OTL38 and fluorescence imaging to detect RCC in partial nephrectomy at the margins of resection, and in lymph node(s) or other metastases during radical nephrectomy.
- Trial name
- NCT02645409
- Testing
- OTL38, Intraoperative fluorescence imaging system
- Where
- 2 sites in United States
- Volunteers
- 14 people
- Sponsor
- Chandru Sundaram
Carcinoma, Renal Cell
A Phase II Uncontrolled Study of BAY73-4506 in Previously Untreated Patients With Metastatic or Unresectable RCC
This is a uncontrolled, open-label, non-randomized Phase II study of oral BAY73-4506 to evaluate the response rate of BAY73-4506 in previously untreated patients with metastatic or unresectable renal cell cancer (RCC).
- Trial name
- NCT00664326
- Testing
- Regorafenib (Stivarga, BAY73-4506)
- Where
- 18 sites in United States, Finland and 4 more
- Volunteers
- 49 people
- Sponsor
- Bayer
Advanced Renal Cell Carcinoma
Software Monitoring of Treatment Related Toxicities in Advanced Renal Cell Carcinoma
To determine if Carevive software, which monitors treatment-related toxicities and then generates self-care management plans for these symptoms, will be feasible to implement among patients with metastatic renal cell carcinoma…
- Trial name
- NCT03229083
- Testing
- Carevive software
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University of Rochester
Metastatic Renal Cell Carcinoma
PF-04856884 (CVX-060) In Combination With Axitinib In Patients With Previously Treated Metastatic Renal Cell Carcinoma
To evaluate the combination of PF-04856884 (CVX-060) in combination with Axitinib (AG-013736) in patients that have received one prior systemic regimen for metastatic renal cell carcinoma (mRCC) vs. axitinib alone.
- Trial name
- NCT01441414
- Testing
- PF-04856884, Axitinib (AG-013736)
- Where
- 29 sites in United States, Czechia
- Volunteers
- 18 people
- Sponsor
- Pfizer
Complete Remission in Renal Cell Carcinoma
Prospective Observational Analysis Of CR With Sunitinib Treatment In mRCC Patients
This prospective study will investigate the characteristics of mRCC patients at time of CR in comparison with mRCC patients non on CR treated with Sunitinib, in order to provide some answers/ refection leads to the following…
- Trial name
- APERCU (NCT01934452)
- Testing
- sunitinib
- Where
- 14 sites in France
- Volunteers
- 77 people
- Sponsor
- Pfizer
Metastatic Melanoma, Metastatic Renal Cell Cancer
Chemotherapy Followed by ESO-1 Lymphocytes and Aldesleukin to Treat Metastatic Cancer
Background: -This study uses an experimental cancer treatment that uses the patient s own lymphocytes (type of white blood cell), which are specially selected and genetically modified to target and destroy their tumor.
- Conditions
- Metastatic Melanoma, Metastatic Renal Cell Cancer, Metastatic Cancer
- Trial name
- NCT00670748
- Testing
- Anti-NY ESO-1 T-cell receptor PBL, aldesleukin, Cyclophosphamide
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- National Cancer Institute (NCI)
Kidney Cancer, Lung Cancer
Cryotherapy and GM-CSF in Treating Patients With Lung Metastases or Primary Lung Cancer
RATIONALE: Cryotherapy kills tumor cells by freezing them. Giving an injection of GM-CSF before cryotherapy and inhaling GM-CSF after cryotherapy may interfere with the growth of tumor cells and shrink the tumor.
- Conditions
- Kidney Cancer, Lung Cancer, Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00514215
- Testing
- sargramostim, flow cytometry, immunoenzyme technique
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Advanced Solid Tumors, Head and Neck Cancer
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
Phase 1a/1b does-escalation study of cabiralizumab alone and with nivolumab in advanced solid tumors.
- Conditions
- Advanced Solid Tumors, Head and Neck Cancer, Pancreatic Cancer, Ovarian Cancer
- Trial name
- FPA008-003 (NCT02526017)
- Testing
- Cabiralizumab, Nivolumab
- Where
- 39 sites in United States
- Volunteers
- 313 people
- Sponsor
- Five Prime Therapeutics, Inc.